
Glucose Data: How Pharmacists Turn Readings Into Next Steps
Key Takeaways
- Pharmacists can move patients from reacting to single glucose values toward recognizing reproducible daily patterns and correlating excursions with diet, activity, and medication timing.
- CGM data support near-real-time education on how lifestyle and pharmacotherapy affect glycemia, but benefits depend on correct data review and interpretation.
Brooke Hudspeth, Nicole Paolini Albanese, and Joshua Neumiller explain how pharmacists spot patterns, fix testing problems, and brief the care team.
Glucose data only improve diabetes care when someone acts on them. Pharmacists are in a position to spot problems in a log or report, sort out the cause, and get a clear summary to the prescriber before the next visit.
"Ultimately, I think we want that monitoring to lead to an action," said Brooke Hudspeth, PharmD, associate dean of pharmacy practice at the University of Kentucky College of Pharmacy,
Finding the Pattern
The first step is moving patients past individual readings. Pharmacists, Hudspeth said, "are really trained to help patients ask what pattern they're seeing with those numbers." She
Pharmacists can then look at what drives the pattern, including food, physical activity, medications, and medication timing, she said.
Continuous glucose monitoring (CGM) makes this easier to show. In a
Troubleshooting Before Escalating
Not every bad number calls for more medication. Some technique problems are easy to fix "if we just watched the patient go through the process," Hudspeth said. One of her patients reported that testing was painful and frustrating. When she demonstrated her technique at the pharmacy, Hudspeth
A simpler device solved the problem. "Sometimes we assume a patient is just not adherent," Hudspeth explained. "But the real problem, I learned, was that we hadn't given her the right tools."
Device factors deserve the same scrutiny. The ADA lists expired or improperly stored test strips, abnormal hematocrit, and low oxygen tension, such as at high altitude, among factors that can distort meter readings. For CGM, patients should rely on a meter while a sensor warms up; some medications, including acetaminophen and vitamin C at certain doses depending on the sensor, can falsely raise sensor values, and adhesive reactions are worth asking about periodically.1
Handing Off to the Care Team
The next step is to make the data usable for the prescriber. Nicole Paolini Albanese, PharmD, CDCES, BCACP, a clinical associate professor at the University at Buffalo School of Pharmacy and Pharmaceutical Sciences,
Albanese said a patient who can explain an outlier, such as "This was an outlier because I was out the night before and I had a bottle of wine," gives the provider a more accurate picture. The pharmacist is there to educate on that so that they can have a good conversation then with their provider, she said.
In some practices, pharmacists can go further. Collaborative practice agreements allow pharmacists to assume increased responsibility, such as initiating, modifying, or discontinuing drug therapy under an agreement with a provider.2
"We know that important gaps exist in use of evidence-based therapies in diabetes, and pharmacists are well positioned to intervene and address gaps related to education, care coordination, access to therapies and technologies, and optimization of guideline-directed therapy," Neumiller said. He sees pharmacists "positioned as a central member of the care team, regardless of practice setting."
REFERENCES
1. American Diabetes Association Professional Practice Committee for Diabetes. 7. Diabetes technology: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl 1):S150-S165. doi:10.2337/dc26-S007
2. Hamilton AL, Darr M. Louisiana state policies prove problematic for pharmacist–physician collaboration. Prev Chronic Dis. 2020;17:E89. Accessed November 18, 2026. https://stacks.cdc.gov/view/cdc/93365/cdc_93365_DS1.pdf
Related to this article








